


X-pand into the Future



December 10, 2013

Assistant Secretary of the Commission for FOI,
Privacy and Sunshine Act Compliance
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, NW
Washington DC 20581

Eurex
Willis Tower
233 South Wacker Drive
Suite 2450
Chicago, IL 60606
USA
T 312 544 1000
F 312 544 1001

Vassilis Vergotis
T 312 544 14771
F 312 544 614771

RE: Petition for Confidential Treatment Pursuant to 17 C.F.R. §§ 37.3(b)(2), 145.5,
145.9

Dear Sir or Madam:

Eurex Deutschland has on this date provided information to update its Foreign Board of Trade Application, as required in Commission Regulation 48.7 to the Division of Market Oversight.

In accordance with the provisions of Commission Regulations 37.3(b)(2), 145.5 and 145.9, we hereby request confidential treatment of the Confidential Submission. Confidential treatment is requested, *inter alia*, on the basis that the Confidential Submission contains information which would separately disclose business information and trade secrets that may not be disclosed to third parties, as provided in Section 8(a) of the Commodity Exchange Act and Commission Regulation 145.5(c)(1). Confidential treatment additionally is requested on the grounds that the Confidential Submission is exempt from disclosure under paragraph (b)(4) of the Freedom of Information Act ("FOIA") and Commission Regulations 145.5(d) and 145.9(d)(1)(ii) because it contains commercial and financial information that is confidential and would be of material assistance to the competitors of Eurex Deutschland.

In accordance with the provisions of paragraph (d)(5) of Regulation 145.9, we request that the Confidential Submission be afforded confidential treatment in perpetuity.

We understand that if the Commission receives a FOIA request for the Confidential Submission, we will be notified of such request in accordance with the Commission's regulations and be asked to submit, within ten business days, a detailed written justification for confidential treatment of the Confidential Submission. See Commission Regulation 149.5(e)(1); see also Executive Order 12600, 52 Fed. Reg.

U.S. Exchange Holdings, Inc.

President
Michael Peters

Executive Vice President
Vassilis Vergotis

23781 (June 23, 1987) (detailing pre-disclosure notification procedures under FOIA). In such event, we request that Commission staff telephone or email the undersigned rather than rely upon United States mail for such notice.

If the Commission or its staff transmits any of the Confidential Submission to another federal agency, we request that you forward a copy of this letter to any such agency with the Confidential Submission and further request that you advise any such agency that Eurex Deutschland has requested that this material be accorded confidential treatment.

The requests set forth in the preceding paragraphs also apply to any memoranda, notes, transcripts or any other writings of any sort whatsoever that are made by, or at the request of, any employee of the Commission (or any other federal agency) and which (1) incorporate, include or relate to any aspect of the Confidential Submission, or (2) refer to any conference, meeting, or telephone conversations between Eurex Deutschland, its current or former employees or consultants, representatives, agents, auditors or counsel on the one hand and employees of the Commission (or any other governmental agency) on the other, relating to the Confidential Submission.

Please acknowledge your receipt of this confidential treatment request by return email to mary.irwin.ext@deutsche-borse.com.

Any questions regarding this request for Confidential Treatment, as well as any notices pursuant to Commission Regulation 145.0€ should be directed to the attention of the undersigned at the telephone number and address set forth herein or Vassilis Vergotis, Executive Vice President, at 312-544-1058.

Yours faithfully,

Mary M. Irwin
Legal Consultant
Eurex Deutschland
Suite 2450
233 South Wacker Drive
Chicago, IL 60606
312-544-1069